New facilities for an extended R&D synthesis laboratory in Beuvry

Minakem, a fine chemistry company serving the life-science industries has started building new facilities for an R&D synthesis laboratory in Beuvry-la-Forêt, close to Lille, North of France, where the group has its headquarters. The investment amounts to a total of USD 2.1 millions, and should be put into operation by the end of 2007. It will be dedicated to the development of new molecules, active principles for the pharmaceutical and cosmetic industries.

Minakem employs an overall of 32 researchers and 13 developers jointly in Beuvry and Leuna (Germany). Every year, Minakem develops around thirty new syntheses for the life-science industry.

The new laboratory will be twice the size of the existing facility, which will be converted to handle industrial process improvement programs and hazardousness studies. It will include the latest research technologies used in organic chemistry in order to face the increasing demand for new synthesis routes.


Source: Minakem

[Read more!]

Creation of PX'Monoclonals

Creation of PX'Monoclonals, a new subsidiary of Protein'eXpert dedicated to the development and production of monoclonal antibodies for research and therapeutic applications

Further to the call for projects issued by LyonBiopole-Mérial, the company PX’Monoclonals has been created in July 2007 and will propose custom research and production services in the monoclonal antibody field by October 2007.

Based in Lyon, PX’Monoclonals will offer services ranging from the generation of high affinity murine antibodies for research and diagnostics applications to the development of humanized and human antibodies for therapeutic purposes. In order to develop a competitive technology platform and to propose innovative approaches, PX’Monoclonals will also initiate internal R&D programmes in collaboration with Biotech companies and academic laboratories.

PX’Monoclonals is a subsidiary of the company Protein’eXpert and will therefore benefit from its experience in terms of enterprise development, technology platform, management and commercialization of research services.

Source: Protein’eXpert

[Read more!]